We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont Rolls Out AmberChrom XT SL to Simplify Biopharma Workflows
Read MoreHide Full Article
Key Takeaways
DD launched AmberChrom XT20 SL and XT30 SL resins for oligonucleotide and peptide purification.
Slurried format removes the hydration step, cutting prep time, simplifying workflows, and lowering costs.
DD's new resins offer high resolution or throughput, with durability for demanding bioprocessing.
DuPont de Nemours, Inc. (DD - Free Report) has launched its DuPont AmberChrom XT SL chromatography resins to enhance efficiency in biopharmaceutical manufacturing and simplify downstream purification workflows.
The company introduced two variants, AmberChrom XT20 SL and AmberChrom XT30 SL, which are designed for the purification of oligonucleotide and peptide therapeutics. These therapies are gaining importance in treating conditions such as genetic disorders, metabolic diseases, and cancer, increasing the need for scalable and efficient purification solutions.
A key feature of the XT SL resins is slurried format. This eliminates the need for a separate hydration step before column packing. As a result, manufacturers can move directly to packing columns, reducing preparation time and simplifying operations. This lowers equipment needs and reduces overall capital costs.
AmberChrom XT20 SL is optimized for high-resolution separations where purity is critical. It supports higher flow rates and offers a balance between resolution and throughput. Both resins provide strong mechanical stability and chemical resistance, ensuring reliable performance under demanding conditions.
The launch strengthens DuPont’s AmberChrom portfolio and reflects its focus on improving efficiency in bioprocessing. The new resins are expected to help manufacturers scale production while maintaining high-quality standards.
Shares of DD have lost 22.8% over the past year against the industry’s 23.5% growth.
Image Source: Zacks Investment Research
DD’s Zacks Rank & Other Key Picks
DD currently carries a Zacks Rank #1 (Strong Buy).
The Zacks Consensus Estimate for CMP’s current-year earnings is pegged at 89 cents per share, indicating a 285.4% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed in the other two, with the average surprise being 34.9%.
The Zacks Consensus Estimate for JMPLY’s current-year earnings is pinned at $4.34 per share, implying a 13.9% year-over-year increase. Shares of JMPLY have surged 75.3% over the past year.
The Zacks Consensus Estimate for AHKSY’s current fiscal-year earnings is pegged at $1.38 per share, indicating a 7.8% year-over-year increase. Shares of AHKSY have surged 48.4% over the past year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
DuPont Rolls Out AmberChrom XT SL to Simplify Biopharma Workflows
Key Takeaways
DuPont de Nemours, Inc. (DD - Free Report) has launched its DuPont AmberChrom XT SL chromatography resins to enhance efficiency in biopharmaceutical manufacturing and simplify downstream purification workflows.
The company introduced two variants, AmberChrom XT20 SL and AmberChrom XT30 SL, which are designed for the purification of oligonucleotide and peptide therapeutics. These therapies are gaining importance in treating conditions such as genetic disorders, metabolic diseases, and cancer, increasing the need for scalable and efficient purification solutions.
A key feature of the XT SL resins is slurried format. This eliminates the need for a separate hydration step before column packing. As a result, manufacturers can move directly to packing columns, reducing preparation time and simplifying operations. This lowers equipment needs and reduces overall capital costs.
AmberChrom XT20 SL is optimized for high-resolution separations where purity is critical. It supports higher flow rates and offers a balance between resolution and throughput. Both resins provide strong mechanical stability and chemical resistance, ensuring reliable performance under demanding conditions.
The launch strengthens DuPont’s AmberChrom portfolio and reflects its focus on improving efficiency in bioprocessing. The new resins are expected to help manufacturers scale production while maintaining high-quality standards.
Shares of DD have lost 22.8% over the past year against the industry’s 23.5% growth.
DD’s Zacks Rank & Other Key Picks
DD currently carries a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the Basic Materials space are Compass Minerals International, Inc. (CMP - Free Report) , Johnson Matthey Plc (JMPLY - Free Report) and Asahi Kasei Corporation (AHKSY - Free Report) . CMP carries a Zacks Rank #1, while JMPLY and AHKSY have a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for CMP’s current-year earnings is pegged at 89 cents per share, indicating a 285.4% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed in the other two, with the average surprise being 34.9%.
The Zacks Consensus Estimate for JMPLY’s current-year earnings is pinned at $4.34 per share, implying a 13.9% year-over-year increase. Shares of JMPLY have surged 75.3% over the past year.
The Zacks Consensus Estimate for AHKSY’s current fiscal-year earnings is pegged at $1.38 per share, indicating a 7.8% year-over-year increase. Shares of AHKSY have surged 48.4% over the past year.